ALPS Medical Breakthroughs ETF SBIO

Morningstar Medalist Rating

Morningstar’s Analysis SBIO

Will SBIO outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ALPS Medical Breakthroughs ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SBIO

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings32.9
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

CG Oncology Inc

5.049M
Healthcare

Oruka Therapeutics Inc

4.498M
Healthcare

Veradermics Inc

3.616M
Healthcare

Dianthus Therapeutics Inc

3.306M
Healthcare

Travere Therapeutics Inc Ordinary Shares

3.166M
Healthcare

Edgewise Therapeutics Inc

3.105M
Healthcare

Definium Therapeutics Inc Ordinary Shares

2.755M
Healthcare

Xenon Pharmaceuticals Inc

2.534M
Healthcare

Viridian Therapeutics Inc

2.484M
Healthcare

Relay Therapeutics Inc Ordinary Shares

2.424M
Healthcare

Sponsor Center